Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

dose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical ... the 9 th Annual Global Pharma Manufacturing ... September 8-9 th . The Global Pharma Manufacturing ... in small molecule and biologic pharmaceutical manufacturing. The ... that today,s manufacturers face, such as the increasing ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... MEETING, Pa. , Aug. 28, 2014 /PRNewswire-USNewswire/ ... community, patients, and media, both for the promise ... patient safety. The quick deployment of surgical robots ... technology are prompting facilities to evaluate their robotic ... the entire surgical team.    ECRI ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... Genoptix, Inc. (Nasdaq: GXDX ) announced today ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... tender offer by Novartis to purchase all outstanding shares of ... The termination of the HSR Act waiting period satisfies one ...
... LA JOLLA, Calif., Feb. 7, 2011 DermTech ... genomic medicine to dermatologists, today announced that the ... melanoma have been published in the British Journal ... EGIR™ technology (Epidermal Genetic Information Retrieval) that non-invasively ...
Cached Medicine Technology:FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act 2Data on DermTech's Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology 2Data on DermTech's Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology 3Data on DermTech's Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology 4
(Date:8/28/2014)... August 29, 2014 The Global and ... on the current state of the Oscilloscope industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/28/2014)... information about the chance of ,overdiagnosis, through the NHS ... involved, according to research published in the British ... a survey of around 2,200 women, Cancer Research UK ... per cent felt they fully understood the information given ... up cancers that would never have gone on to ...
(Date:8/28/2014)... Arizona State University graduate student Anthony Gonzales, co-founder ... one of five finalists in Entrepreneur magazine’s 2014 College ... fourth consecutive year that an ASU student has been ... SafeSIPP, and JJ Tang, co-founder of Vantage Realized, were ... dominated the competition: Three of the five finalists were ...
(Date:8/28/2014)... exit strategy from the war, now may be the time ... to veterans, says a Perspective piece in the New ... doing more of the same is to fail to recognize ... structure pose in the longer run," said William Weeks, from ... David Auerbach, from the RAND Corporation, in the August issue ...
(Date:8/28/2014)... 2014 Allegheny Health Network ... regional partnership designed to advance sports nutrition education, ... young athletes, scholastic athletes and their families across ... & Mind Initiative will offer a comprehensive and ... and mental dynamics involved in pursuing athletic excellence,” ...
Breaking Medicine News(10 mins):Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 3Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:A VA exit strategy 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... in an attempt to find out how various eating ... the blood pressures of meat eaters, fish eaters, vegetarians, ... Health Nutrition, showed how healthy eating habits could help ... in the comparative study - some with high blood ...
... on birth control pills have been linking them to ... pills. However, a new study published by Walter Spitzer, ... contradicted previous studies by stating that women who take ... no increased risk for heart attack compared to women ...
... observed a pill-sized camera and a CT scan may prove ... small intestine. The newly approved camera capsule, also known as ... before available. A patient swallows the pill and, for eight ... on the person's abdomen.// The pictures can then be viewed ...
... have discovered that it might be possible for tear-free GM ... the chemical in onions that makes you cry is not ... of Tokyo and Kyoto University,//tested the theory that the crying ... Alliinase plays a part in the chemical reactions that give ...
... that cloned animals tend to harbor genetic defects that ... the rational that reproductive cloning of humans should be ... be used safely for therapeutic cloning techniques, such as ... Parkinson's to diabetes. Cloned animals have major ...
... shown in a new study, that soy can lower cholesterol ... studies give more reason to dish up the soy protein ... fatty acids, which are found in abundance in fish, //flax ... health benefits. But researchers suggest they also produce physiological effects ...
Cached Medicine News:Health News:Cut meat to cut blood pressure 2Health News:No heart attack risk for women taking birth control pills 2Health News:Genetic failure in cloned animals 2Health News:Soy, Omega 3s convalesce artery health 2Health News:Soy, Omega 3s convalesce artery health 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: